Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 991 to 1005 of 1328 results for nice quality standards or clinical guidelines

  1. What NICE does

    We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  2. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

  3. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  4. Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people with multimorbidity who may not benefit from continuing them?

    NG56/3 Question Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people...

  5. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .

  6. Knowledge transfer seminars

    Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing

  7. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

  8. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  9. Obinutuzumab for untreated advanced follicular lymphoma (TA513)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

  10. Myocardial infarction: medication for MI in preceding 12 months (IND125)

    This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79

  11. Icare rebound tonometer to measure intraocular pressure (MIB57)

    NICE has developed a medtech innovation briefing (MIB) on the Icare rebound tonometer to measure intraocular pressure

  12. Using our recommendations: maternity and neonatal health

    How to use NICE guidance to reduce health inequalities during and after pregnancy.

  13. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

  14. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

  15. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment (HTG739)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care.